| 59.4% |  | United States |
| 8.7% |  | United Kingdom |
| 5% |  | Canada |
| 4% |  | Australia |
| 3.5% |  | Philippines |
| 2.6% |  | Netherlands |
| 2.4% |  | India |
| 1.6% |  | Germany |
| 1% |  | France |
| 0.7% |  | Poland |
| Today: | 207 |
| Yesterday: | 251 |
| This Week: | 207 |
| Last Week: | 2221 |
| This Month: | 4795 |
| Last Month: | 6796 |
| Total: | 129394 |
Further reading
Written by EMCDDA | 
| 
| 
| Reports - EMCDDA Report on the risk assessment of PMMA |
Drug Abuse
Other EMCDDA publications in the field of new synthetic drugs and implementation of the joint action
EMCDDA Insights series
New trends in synthetic drugs in the European Union: epidemiology
and demand-reduction responses
Insights series No 1
Published: 1997
ISBN: 92-9168-030-3
Price: EUR 20.50
Implementation of the joint action
Report on the risk assessment of GHB in the framework of the joint action on new
synthetic drugs
Published: 2002
ISBN: 92-9168-122-9
Price: Free
Report on the risk assessment of ketamine in the framework of the joint action on
new synthetic drugs
Published: 2002
ISBN: 92-9168-123-7
Price: Free
Report on the risk assessment of 4-MTA in the framework of the joint action on new
synthetic drugs
Published: 1999
ISBN: 92-9168-087-7
Price: Free
Report on the risk assessment of MBDB in the framework of the joint action
on new synthetic drugs
Published: 1999
ISBN: 92-9168-063-X
Price: Free
Guidelines for the risk assessment of new synthetic drugs
Published: 1999
ISBN: 92-9168-061-3
Price: Free
| < Prev |
|---|